Keyvan Rezaï

3.5k total citations · 2 hit papers
78 papers, 2.3k citations indexed

About

Keyvan Rezaï is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Keyvan Rezaï has authored 78 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 32 papers in Oncology and 19 papers in Hematology. Recurrent topics in Keyvan Rezaï's work include Protein Degradation and Inhibitors (20 papers), Multiple Myeloma Research and Treatments (16 papers) and HER2/EGFR in Cancer Research (11 papers). Keyvan Rezaï is often cited by papers focused on Protein Degradation and Inhibitors (20 papers), Multiple Myeloma Research and Treatments (16 papers) and HER2/EGFR in Cancer Research (11 papers). Keyvan Rezaï collaborates with scholars based in France, United States and Switzerland. Keyvan Rezaï's co-authors include François Lokiec, Gordon M. Trenholme, Miguel G. Madariaga, Robert A. Weinstein, Patrice Herait, Mohamed Békradda, Carmen Kahatt, Anastasios Stathis, María E. Riveiro and Esteban Cvitkovic and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Keyvan Rezaï

75 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

2016 336 citations Keyvan Rezaï, Carmen Kahatt et al. profile →
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

2016 328 citations Anastasios Stathis, Keyvan Rezaï et al. profile →

Peers

Countries citing papers authored by Keyvan Rezaï

Since Specialization

Citations

This map shows the geographic impact of Keyvan Rezaï's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keyvan Rezaï with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keyvan Rezaï more than expected).

Fields of papers citing papers by Keyvan Rezaï

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keyvan Rezaï. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keyvan Rezaï. The network helps show where Keyvan Rezaï may publish in the future.

Co-authorship network of co-authors of Keyvan Rezaï

This figure shows the co-authorship network connecting the top 25 collaborators of Keyvan Rezaï. A scholar is included among the top collaborators of Keyvan Rezaï based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keyvan Rezaï. Keyvan Rezaï is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study 2025 ·Cancer Research Communications ·William C. Reinhold, Elisabetta Marangoni, Fathi Elloumi, Rémi Montagne, Sudhir Varma, (unknown), Keyvan Rezaï, (unknown), Ahmed Dahmani, Rania El Botty, Léa Huguet, (unknown), Naoko Takebe, Samuel Huguet, Augustin Luna, Yves Pommier	1
2	Application of an Environmental Monitoring to Assess the Practices and Control the Risk of Occupational Exposure to Cyclophosphamide in Two Sites of a French Comprehensive Cancer Center 2022 ·Annals of Work Exposures and Health ·(unknown), (unknown), (unknown), Samuel Huguet, Keyvan Rezaï, (unknown), (unknown)	10
3	Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights, and ADME-Tox profile 2021 ·European Journal of Medicinal Chemistry ·Simona Sestito, (unknown), (unknown), Massimiliano Runfola, Francesca Gado, Eleonora Margheritis, Sheraz Gul, María E. Riveiro, Ramiro Vázquez, Samuel Huguet, Clementina Manera, Keyvan Rezaï, G. Garau, Simona Rapposelli	8
4	Ultra‐fast liquid chromatography method coupled with ultraviolet detection to quantify dimethylsulfoxide, dimethylformamide and dimethylacetamide in short half‐lives radiopharmaceuticals 2021 ·Journal of Labelled Compounds and Radiopharmaceuticals ·(unknown), (unknown), Samuel Huguet, (unknown), (unknown), Keyvan Rezaï, (unknown)	2
5	Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy 2021 ·Frontiers in Oncology ·Ramiro Vázquez, María E. Riveiro, (unknown), (unknown), Julie A. Gormley, Olivier Touzelet, Keyvan Rezaï, Mohamed Békradda, L’Houcine Ouafik	25
6	Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP 2019 ·Cancer Chemotherapy and Pharmacology ·(unknown), Samuel Huguet, Anne‐Laure Couderc, Pascal Chaı̈bi, (unknown), Christiane Verny, (unknown), (unknown), Saı̈k Urien, Keyvan Rezaï	7
7	BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance 2018 ·ESMO Open ·Chiara Tarantelli, Elena Bernasconi, Eugenio Gaudio, Luciano Cascione, (unknown), Alberto J. Arribas, Filippo Spriano, Andrea Rinaldi, Afua A. Mensah, Ivo Kwee, Maurilio Ponzoni, Emanuele Zucca, Laura Carrassa, María E. Riveiro, Keyvan Rezaï, Anastasios Stathis, Esteban Cvitkovic, Francesco Bertoni	21
8	PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer 2017 ·European Journal of Cancer ·Mathilde Guérin, Keyvan Rezaï, Nicolás Isambert, Mario Campone, A Autret, Jihane Pakradouni, Magali Provansal, Jacques Camerlo, Renaud Sabatier, François Bertucci, Emmanuelle Charafe‐Jauffret, Alice Hervieu, Jean-Marc Extra, Patrice Viens, François Lokiec, Jean‐Marie Boher, Anthony Gonçalvès	45
9	Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non‐metastatic breast cancer 2015 ·British Journal of Clinical Pharmacology ·(unknown), Mario Campone, Jean‐Louis Merlin, Valérie Gouilleux‐Gruart, Thomas Bachelot, François Lokiec, Keyvan Rezaï, Mónica Arnedos, Véronique Dièras, (unknown), Gilles Paintaud, David Ternant	25
10	A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study) 2014 ·The Breast ·P. Fumoleau, Kevin M. Koch, Étienne Brain, François Lokiec, Keyvan Rezaï, Ahmad Awada, Larry Hayward, Gustavo Werutsky, Jan Bogaerts, Sandrine Marréaud, Fátima Cardoso	10
11	Extracellular Adenosine Triphosphate Affects the Response of Human Macrophages Infected With Mycobacterium tuberculosis 2014 ·The Journal of Infectious Diseases ·(unknown), (unknown), Luis B. Barreiro, Sylvère Durand, Guillaume Soubigou, Cécile Lecointe, Jihène Klibi, Keyvan Rezaï, François Lokiec, Jean‐Yves Coppée, Brigitte Gicquel, Ludovic Tailleux	17
12	Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer 2013 ·Cancer Chemotherapy and Pharmacology ·Amita Patnaik, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Muralidhar Beeram, Saı̈k Urien, Larry J. Schaaf, Sanaa Tahiri, Tanios Bekaii‐Saab, François Lokiec, Keyvan Rezaï, Aby Buchbinder	44
13	Safety, pharmacokinetics, and activity of EZN‐2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies 2012 ·Cancer ·Razelle Kurzrock, Sanjay Goel, Jennifer J. Wheler, David S. Hong, Siqing Fu, Keyvan Rezaï, (unknown), Saı̈k Urien, Sridhar Mani, Imran Chaudhary, (unknown), Aby Buchbinder, François Lokiec, Mary F. Mulcahy	38
14	Surgical Management of Endocarditis: The Society of Thoracic Surgeons Clinical Practice Guideline 2011 ·The Annals of Thoracic Surgery ·John G. Byrne, Keyvan Rezaï, Juan A. Sánchez, Richard A. Bernstein, Eric Okum, Marzia Leacche, Jorge M. Balaguer, Shyam Prabhakaran, Charles R. Bridges, Robert Higgins	115
15	Platination of telomeric DNA by cisplatin disrupts recognition by TRF2 and TRF1 2010 ·JBIC Journal of Biological Inorganic Chemistry ·Isabelle Ourliac‐Garnier, Anaïs Poulet, (unknown), Simon Amiard, Frédérique Magdinier, Keyvan Rezaï, Éric Gilson, Marie‐Josèphe Giraud‐Panis, Sophie Bombard	10
16	Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients 2010 ·British Journal of Cancer ·Anne Fajac, Joseph Gligorov, Keyvan Rezaï, Pierre Lévy, E. Lévy, Frédèric Selle, K. Beerblock, D. Avenin, Pierre Saintigny, (unknown), Jean‐François Bernaudin, François Lokiec	28
17	ABCB1 (MDR1) genotype in relation to doxorubicin and docetaxel pharmacokinetics in patients with breast cancer 2007 ·Cancer Research ·Joseph Gligorov, Frédèric Selle, Éric Levy, K. Beerblock, Pierre Saintigny, (unknown), Jean‐Pierre Lotz, Keyvan Rezaï, Jean‐François Bernaudin, Serge Uzan, Pierre Lévy, François Lokiec, Anne Fajac	1
18	Pharmacokinetics, Metabolism, and Routes of Excretion of Intravenous Irofulven in Patients with Advanced Solid Tumors 2006 ·Drug Metabolism and Disposition ·Angélo Paci, Keyvan Rezaï, Alain Deroussent, Dominique de Valeriola, Micheline Ré, (unknown), Esteban Cvitkovic, Carmen Kahatt, Ajit Shah, Stephen J. Waters, (unknown), Gilles Vassal, François Lokiec	9
19	Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer 2006 ·Gynecologic Oncology ·Sameer Sharma, Keyvan Rezaï, Deborah Driscoll, Kunle Odunsi, Shashikant Lele	12
20	Q fever: a biological weapon in your backyard 2003 ·The Lancet Infectious Diseases ·Miguel G. Madariaga, Keyvan Rezaï, Gordon M. Trenholme, Robert A. Weinstein	229

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact